Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Gilead (Nasdaq: GILD) hit a new 52-week high Friday as it is currently trading at $55.34, above its previous 52-week high of $55.16 with 1.7 million shares traded as of 9:35 a.m. ET. Average volume has been 11 million shares over the past 30 days. Gilead has a market cap of $76.41 billion and is part of the health care sector and drugs industry. Shares are up 36.5% year to date as of the close of trading on Thursday. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. The company has a P/E ratio of 30.6, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Gilead Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.